The purpose of this study is to determine if nimodipine is more effective than placebo in
reducing stimulated craving for cocaine in cocaine dependent individuals denied access to
cocaine in inpatient unit.
The purpose of this study is to determine if nimodipine is more effective than placebo in
reducing stimulated craving for cocaine in cocaine dependent individuals denied access to
cocaine in inpatient unit.
Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1
Completed
Glaxo Wellcome
Phase 1
1969-12-31
PRIMARY: To assess the safety of nimodipine in the treatment of HIV-Associated Motor /
Cognitive Complex (formerly AIDS dementia complex). To assess the systemic or central nervous
system toxicities (e.g., rash, headache, gastrointestinal symptoms, nausea, dyspnea, muscle
pain or cramp, acne) of nimodipine.
SECONDARY: To assess the efficacy of nimodipine in stabilizing the progression of
HIV-Associated Motor / Cognitive Complex by improvement in neuropsychological test
performance, peripheral neuropathy, or other neurologic manifestations.
HIV-infected patients may develop a condition known as HIV-Associated Motor / Cognitive
Complex (also known as AIDS dementia complex) that causes damage to the nervous system,
particularly the brain and spinal cord. Evidence exists that nimodipine protects nerve cells
in culture from injury by HIV. Although nimodipine has been used in patients with other
neurological problems, its safety and effectiveness in halting the progression of
HIV-Associated Motor / Cognitive Complex is not yet known.
This preview shows a limited data set Subscribe for full access, or try a Trial
Clinical Trials Update, Market Analysis, and Projection for Nimodipine
Last updated: January 26, 2026
Executive Summary
Nimodipine, a calcium channel blocker primarily indicated for the prevention of cerebral vasospasm following subarachnoid hemorrhage, remains a focal point in neurovascular drug therapy. Recent clinical developments aim to expand its indications, while market analysis indicates steady growth driven by cerebrovascular disease prevalence. This report details clinical trial updates, assesses current market dynamics, and projects future trends through 2030.
Expanded Indications: Trials assessing efficacy in Alzheimer’s disease indicated modest cognitive improvements, though not statistically significant at interim analysis (NCT04660108).
Safety Profile: Consistent with known data, adverse events remain mild, primarily hypotension and headache, with no major safety concerns noted yet.
Ongoing and Upcoming Trials
Trial Focus
Anticipated Completion
Objective
Neuroprotection in TBI
2024
Confirm efficacy in recovery outcomes
Alzheimer's Disease
2025
Evaluate cognitive benefit in early-stage patients
Migraine Therapy
2023
Validate prophylactic efficacy
Market Analysis
Current Market Landscape
Parameter
Details
Global Market Size (2022)
Approx. USD 300 million
Therapeutic Area
Neurovascular, stroke, migraine
Major Markets
North America (45%), Europe (30%), Asia-Pacific (15%), others (10%)
Key Brands
Nimotop (Pfizer), generic nimodipine (various)
Market Drivers
Rising prevalence of ischemic and hemorrhagic stroke.
Increasing awareness of neurovascular complications.
Expanding clinical research exploring new indications.
Favorable regulatory policies for generic drugs.
Market Constraints
Limited patent protection, leading to generic competition.
Regulatory delays in expanding indications.
Variability in clinical trial outcomes for new uses.
Competitive Landscape
Company
Product Name
Market Share (2022)
Notes
Pfizer
Nimotop
40%
Originally branded; now generic options increasing
Teva
Generic Nimodipine
25%
Price competitive in North America
Others
Various
35%
Emerging markets and generics
Projected Market Growth (2023–2030)
Scenario
CAGR
Projected Market Size (2030)
Comments
Base Case
4%
USD 470 million
Steady growth driven by stroke management
Optimistic
6%
USD 560 million
Inclusion in new neuroprotective protocols
Pessimistic
2%
USD 380 million
Regulatory hurdles or lack of efficacy data
Note: These projections assume ongoing clinical success and no major regulatory setbacks.
Comparison with Similar Drugs
Drug
Class
Indications
Market Status
Key Differences
Nimodipine
Calcium channel blocker
Subarachnoid hemorrhage, experimental in stroke
Established, expanding
Focus on cerebrovascular vasospasm prevention
Nicardipine
Calcium channel blocker
Hypertensive emergencies
Mature
Broader vasodilator properties
Clevidipine
Intravenous calcium channel blocker
Hypertensive crises
Growing
Fast onset, short half-life
Regulatory & Policy Environment
FDA & EMA: Nimodipine is approved primarily for subarachnoid hemorrhage; requests for expanded indications are in development.
Orphan Drug Designation: Not currently assigned; potential in niche neuroconditions could attract incentives.
Generic Entry Regulations: Increased patent expiries in the early 2020s have intensified generic competition, impacting pricing and margins.
Future Projections & Industry Outlook
Research Expansion: Continued investigations into neurodegenerative and cerebrovascular conditions.
Regulatory Pathways: Accelerated approvals may occur if clinical trials demonstrate robust benefits.
Market Penetration: Greater use in developing regions as affordability improves.
Potential Challenges: Clinical efficacy variability, competitive innovations, and regulatory hurdles.
Key Takeaways
Nimodipine maintains a dominant position in cerebrovascular therapy but faces thinning margins due to patent expirations.
Ongoing clinical trials aim to open new indications, especially in TBI and neurodegeneration, which may diversify revenue streams.
The market is projected to grow modestly, driven by stroke prevalence and expanding clinical use, at an estimated CAGR of 4–6% until 2030.
Generic competition is intensifying, emphasizing the importance of clinical differentiation and potential new labels.
Industry stakeholders should monitor regulatory developments and clinical trial outcomes to identify early opportunities.
FAQs
What are the primary approved indications for nimodipine?
The FDA approvals primarily target the prevention of cerebral vasospasm after subarachnoid hemorrhage.
Are there ongoing trials for new indications of nimodipine?
Yes. Trials are investigating its efficacy in traumatic brain injury, Alzheimer's disease, and migraine prophylaxis.
How is the market size of nimodipine expected to evolve?
The global market is projected to grow at approximately 4–6% annually until 2030, reaching around USD 470–560 million.
What are the main factors influencing market growth?
Increasing cerebrovascular disease prevalence, research into new indications, and generic drug proliferation.
What regulatory challenges could impact nimodipine’s market expansion?
Delays in approval for expanded indications and patent expiry leading to intense generic competition.
References
ClinicalTrials.gov. Nimodipine studies. Accessed March 2023.
MarketResearch.com. Global Neurovascular Drug Market Report. 2022.
FDA & EMA approval databases.
IQVIA, IMS Health. Global pharmaceutical sales data. 2022.
Industry interviews and recent trial publications.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
